表紙
市場調查報告書

PharmSource:基因治療 - 醫藥品受託製造機關 (CMO) 的市場機會

PharmSource - Gene Therapy Market Opportunity for CMOs - 2019 Edition

出版商 GlobalData 商品編碼 919466
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
PharmSource:基因治療 - 醫藥品受託製造機關 (CMO) 的市場機會 PharmSource - Gene Therapy Market Opportunity for CMOs - 2019 Edition
出版日期: 2019年12月16日內容資訊: 英文 47 Pages
簡介

本報告提供全球醫藥品受託製造機關 (CMO) 的基因治療的市場機會相關分析,基因治療的概要和目前技術水準,現在臨床實驗中的開發中產品/技術的概要與認證預測,相關產業結構 (大企業的策略展開情形等),未來需求結構與趨勢預測等資訊彙整,為您概述為以下內容。

目錄

  • 摘要整理
  • 簡介
  • 在民間的基因治療的體驗
  • 基因治療的開發平台
  • 病毒載體的不足
  • 臨床實驗認證預測
  • 基因治療的供應鏈
  • 需求模式
  • 結論
  • 分析方法:註記
  • 附錄
目錄
Product Code: GDPS0028MAR

This report will explore whether the bio/pharma industry is adequately prepared for future gene therapy developments and whether CDMOs are making appropriate investments in the capacity and technology to support the coming opportunity. This report is a companion to Cell Therapy Market Opportunity for CMOs - 2018 Edition, GlobalData PharmSource, July 2018.

This report will explore whether the bio/pharma industry is adequately prepared for future gene therapy developments and whether CDMOs are making appropriate investments in the capacity and technology to support the coming opportunity.

Scope

  • This 47-page report gives important, expert insight you won't find in any other source. 28 tables and figures throughout the report illustrate major points and trends. This report is required reading for:
  • CMO executives who must have deep understanding of the gene therapy marketplace to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Pharmaceutical and Biotech companies involved in the development of gene therapies or gene therapy technologies.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to buy

  • What are the characteristics of the gene therapy pipeline?
  • What volumes of viral vector will be required by 2024 for clinical and commercial gene therapy manufacturing, and how many bioreactors will be needed?
  • How many gene therapies from the current clinical pipeline are predicted to be approved?
  • What gene therapies have been approved by the FDA and EMA to date?
  • What is the geographic reach of gene therapy contract manufacturing organizations and what methods of transfection do they use?
  • What are the steps in the in vivo and ex vivo gene therapy supply chains?
  • What is the contract manufacturing organization opportunity for gene therapies?
  • What are the top therapy areas and indications for gene therapy clinical trials, 2013-2019?
  • How can the gene therapy manufacturing process be made more efficient?
  • What investments have contract manufacturing organizations and bio/pharmaceutical companies made in gene therapy manufacturing facilities and technologies?

Table of Contents

  • Executive Summary
  • Introduction
  • Commercial Gene Therapy Experience
  • Gene Therapy Pipeline
  • The Viral Vector Shortage
  • Approvals Outlook
  • Gene Therapy Supply Chain
  • Demand Models
  • What It Means
  • Notes on Methodology
  • Appendix

List of Tables

  • Table 1: FDA-Approved, Marketed Gene Therapies
  • Table 2: EMA-Approved, Marketed Gene Therapies
  • Table 3: Top 10 Gene Therapy Sponsor Companies, All Development Stages
  • Table 4: Top 10 Gene Therapy Sponsor Companies, Phases I-III
  • Table 5: Predicted Gene Therapy Approvals
  • Table 6: Gene Therapy CMO Sites and their Methods of Transfection
  • Table 7: Model for Zolgensma and Luxturna Viral Vector Commercial Requirements, 2024
  • Table 8: Model for Yearly Commercial Gene Therapy Viral Vector Requirements
  • Table 9: Model for Yearly Clinical Gene Therapy Viral Vector Requirements
  • Table 10: Model for AAV Bioreactor Capacity
  • Table 11: Model for Lentiviral Bioreactor Capacity
  • Table 12: Forecast: Annual Viral Vector Bioreactor Capacity for Clinical and Commercial Gene Therapy
  • Table 13: Likelihood of Approval "N" values for Gene Therapy

List of Figures

  • Figure 1: Zolgensma Global Sales Forecast, 2019-2024 ($M)
  • Figure 2: Luxturna Global Sales Forecast 2019-2024 ($M)
  • Figure 3: Pipeline Gene Therapy Drugs by Stage
  • Figure 4: Phase I-III Gene Therapy Trial Starts by Sponsor Type
  • Figure 5: Phase I Gene Therapy Trial Starts by Sponsor Type
  • Figure 6: Phase II Gene Therapy Trial Starts by Sponsor Type
  • Figure 7: Phase III Gene Therapy Trial Starts by Sponsor Type
  • Figure 8: Top Ten Sponsors of Phase I-III Gene Therapy Trials, 2013-2019
  • Figure 9: Top Five Therapy Areas in Gene Therapy Trials, 2013-2019
  • Figure 10: Top Seven Indications in Gene Therapy Trials, 2013-2019
  • Figure 11: Reasons for Discontinuations of Gene Therapy Trials, 2013-2019
  • Figure 12: Top Gene Therapy CMOs by Number of Gene Therapy Facilities
  • Figure 13: Gene Therapy CDMOs by Number of Gene Therapy Facilities
  • Figure 14: Geographic Spread of Dedicated Contract Gene Therapy Contract Manufacturing Facilities
  • Figure 15: Geographic Spread of Excess Capacity Gene Therapy Contract Manufacturing Facilities
Back to Top